Page 112

Reflect Scientific Awarded Patent for COVID Vaccine Capable- Self Powered, Low Temperature Controlled Bulk Shipping System

By Dr. Matthew Watson

Go here to see the original:
Reflect Scientific Awarded Patent for COVID Vaccine Capable- Self Powered, Low Temperature Controlled Bulk Shipping System

To Read More: Reflect Scientific Awarded Patent for COVID Vaccine Capable- Self Powered, Low Temperature Controlled Bulk Shipping System
categoriaGlobal News Feed commentoComments Off on Reflect Scientific Awarded Patent for COVID Vaccine Capable- Self Powered, Low Temperature Controlled Bulk Shipping System | dataOctober 19th, 2020
Read All

Cocrystal Pharma Provides Update on Influenza A Program

By Dr. Matthew Watson

– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain –

View post:
Cocrystal Pharma Provides Update on Influenza A Program

To Read More: Cocrystal Pharma Provides Update on Influenza A Program
categoriaGlobal News Feed commentoComments Off on Cocrystal Pharma Provides Update on Influenza A Program | dataOctober 19th, 2020
Read All

Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update

By Dr. Matthew Watson

DAVIS, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, today released a letter to shareholders from Chief Executive Officer, Kevin Helash.

Continued here:
Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update

To Read More: Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update
categoriaGlobal News Feed commentoComments Off on Marrone Bio Innovations Issues Shareholder Letter and Provides Operational Update | dataOctober 19th, 2020
Read All

Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners

By Dr. Matthew Watson

NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Scott Henry, Managing Director, Senior Research Analyst and Head of Pharmaceuticals Research at ROTH Capital Partners, will host a webinar with the management team of Journey Medical Corporation (“Journey Medical”), a partner company of Fortress, on Wednesday, October 21, 2020, at 1:00 p.m. EDT. Speakers from Journey Medical will include Claude Maraoui, President and Chief Executive Officer, Robert Nevin, Chief Commercial Officer, and Nirav Jhaveri, Chief Financial Officer.

See the rest here:
Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners

To Read More: Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners
categoriaGlobal News Feed commentoComments Off on Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners | dataOctober 19th, 2020
Read All

Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call

By Dr. Matthew Watson

JERSEY, Channel Islands, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2020 will be released before market open on Monday, Nov 2, 2020.

More:
Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call

To Read More: Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call
categoriaGlobal News Feed commentoComments Off on Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call | dataOctober 19th, 2020
Read All

22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and…

By Dr. Matthew Watson

The U.S. Food and Drug Administration to provide an update on the Agency’s Comprehensive Plan for Tobacco and Nicotine Regulation The U.S. Food and Drug Administration to provide an update on the Agency’s Comprehensive Plan for Tobacco and Nicotine Regulation

See more here:
22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and...

To Read More: 22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and…
categoriaGlobal News Feed commentoComments Off on 22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute’s Tobacco and Nicotine Products Regulation and… | dataOctober 19th, 2020
Read All

Rafarma Closes Biocogency Merger

By Dr. Matthew Watson

Nicosia, Cyprus, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES. The new consolidated financials will include Slavich (http://www.slavich.ru), Slavich Trading House and related companies based in Spain, Ireland and Cyprus, with Kras Pharma (http://kraspharma.ru) and Bebig (http://en.bebig.ru/) being added in due course.

Read more from the original source:
Rafarma Closes Biocogency Merger

To Read More: Rafarma Closes Biocogency Merger
categoriaGlobal News Feed commentoComments Off on Rafarma Closes Biocogency Merger | dataOctober 19th, 2020
Read All

Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020

By Dr. Matthew Watson

DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of Nephrology (ASN) Kidney Week 2020, which is being held virtually from October 22-25, 2020. The abstracts will highlight clinical and nonclinical data from novel drug formulations being developed for the treatment of chronic kidney disease (CKD), acute kidney injury (AKI), and COVID-19.

Read the original post:
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020

To Read More: Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020
categoriaGlobal News Feed commentoComments Off on Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020 | dataOctober 19th, 2020
Read All

Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call

By Dr. Matthew Watson

MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial Results on Monday, November 2, 2020, at 4:30pm Eastern Time.

More here:
Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call

To Read More: Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call
categoriaGlobal News Feed commentoComments Off on Pacific Biosciences of California, Inc. Third Quarter 2020 Financial Results Call | dataOctober 19th, 2020
Read All

Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR…

By Dr. Matthew Watson

New in vivo data for colon cancer show anti-tumor immunity in 100% of mice

See the article here:
Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR...

To Read More: Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR…
categoriaGlobal News Feed commentoComments Off on Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR… | dataOctober 19th, 2020
Read All

Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results

By Dr. Matthew Watson

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on October 29, 2020, to discuss its third quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 7374769.

Link:
Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results

To Read More: Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results
categoriaGlobal News Feed commentoComments Off on Constellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 Results | dataOctober 19th, 2020
Read All

Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci

By Dr. Matthew Watson

Daix (France), October 19, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to odiparcil, the Company’s clinical-stage drug candidate for the treatment of MPS type VI (MPS VI), a rare and progressive genetic disorder.

See more here:
Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci

To Read More: Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci
categoriaGlobal News Feed commentoComments Off on Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci | dataOctober 19th, 2020
Read All

Orion upgrades full-year outlook for 2020

By Dr. Matthew Watson

ORION CORPORATION STOCK EXCHANGE RELEASE INSIDE INFORMATION 19 OCTOBER 2020 at 20.35 EEST

The rest is here:
Orion upgrades full-year outlook for 2020

To Read More: Orion upgrades full-year outlook for 2020
categoriaGlobal News Feed commentoComments Off on Orion upgrades full-year outlook for 2020 | dataOctober 19th, 2020
Read All

Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call

By Dr. Matthew Watson

MALVERN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release third quarter 2020 financial and operating results after market close on Monday, November 2, 2020. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

Read the rest here:
Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call

To Read More: Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call
categoriaGlobal News Feed commentoComments Off on Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call | dataOctober 19th, 2020
Read All

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

By Dr. Matthew Watson

ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and selectivity for exon 20 insertion mutations of EGFR and HER2

Originally posted here:
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

To Read More: ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program
categoriaGlobal News Feed commentoComments Off on ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program | dataOctober 19th, 2020
Read All

Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020

By Dr. Matthew Watson

EMERYVILLE, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be report financial results for the third quarter 2020 after market close on Thursday, November 12, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

See more here:
Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020

To Read More: Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020
categoriaGlobal News Feed commentoComments Off on Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020 | dataOctober 19th, 2020
Read All

Replimune Appoints Tanya Lewis to the Board of Directors

By Dr. Matthew Watson

WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of November 2, 2020.

Read the original post:
Replimune Appoints Tanya Lewis to the Board of Directors

To Read More: Replimune Appoints Tanya Lewis to the Board of Directors
categoriaGlobal News Feed commentoComments Off on Replimune Appoints Tanya Lewis to the Board of Directors | dataOctober 19th, 2020
Read All

Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member

By Dr. Matthew Watson

John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board

Continued here:
Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member

To Read More: Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member
categoriaGlobal News Feed commentoComments Off on Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member | dataOctober 19th, 2020
Read All

Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

By Dr. Matthew Watson

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

Originally posted here:
Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

To Read More: Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
categoriaGlobal News Feed commentoComments Off on Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 | dataOctober 19th, 2020
Read All

UPDATE — Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

By Dr. Matthew Watson

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

View post:
UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

To Read More: UPDATE — Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
categoriaGlobal News Feed commentoComments Off on UPDATE — Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 | dataOctober 19th, 2020
Read All

Page 112